Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Beilstein Journal of Nanotechnology
|
June 24, 2016
In situ observation of deformation processes in nanocrystalline face-centered cubic metals
Aaron Kobler, Christian Brandl, Horst Hahn, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
August 31, 2017
Self-Healing and Shape Memory Effects in Gold Microparticles through the Defects-Mediated Diffusion
Oleg Kovalenko, Christian Brandl, Leonid Klinger, et al.
ACS Omega
|
October 16, 2023
Rigidity-Induced Controlled Aggregation of Binary Colloids
Zakiya Shireen, Tine Curk, Christian Brandl, et al.
Cell and Tissue Research
|
October 14, 2004
Mas-allatotropin/Lom-AG-myotropin I immunostaining in the brain of the locust, Schistocerca gregaria
Uwe Homberg, Christian Brandl, Elke Clynen, et al.
Clinical Pharmacokinetics
|
May 23, 2016
Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
Min Zhu, Benjamin Wu, Christian Brandl, et al.
Langmuir : the ACS Journal of Surfaces and Colloids
|
January 27, 2016
Adsorption Studies of Organophosphonic Acids on Differently Activated Gold Surfaces
Katrin Niegelhell, Simon Leimgruber, Thomas Grießer, et al.
Journal of Clinical Pharmacology
|
September 19, 2017
Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia
Min Zhu, Andrea Kratzer, Jessica Johnson, et al.
International Journal of Cancer
|
February 3, 2005
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
Patrick Hoffmann, Robert Hofmeister, Klaus Brischwein, et al.
International Journal of Cancer
|
September 5, 2002
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
Torsten Dreier, Grit Lorenczewski, Christian Brandl, et al.
Clinical Pharmacokinetics
|
November 26, 2024
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE<sup>®</sup>) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
Mukul Minocha, Corbin G Thompson, Alexis Murphy, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Beilstein Journal of Nanotechnology
|
June 24, 2016
In situ observation of deformation processes in nanocrystalline face-centered cubic metals
Aaron Kobler, Christian Brandl, Horst Hahn, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
August 31, 2017
Self-Healing and Shape Memory Effects in Gold Microparticles through the Defects-Mediated Diffusion
Oleg Kovalenko, Christian Brandl, Leonid Klinger, et al.
ACS Omega
|
October 16, 2023
Rigidity-Induced Controlled Aggregation of Binary Colloids
Zakiya Shireen, Tine Curk, Christian Brandl, et al.
Cell and Tissue Research
|
October 14, 2004
Mas-allatotropin/Lom-AG-myotropin I immunostaining in the brain of the locust, Schistocerca gregaria
Uwe Homberg, Christian Brandl, Elke Clynen, et al.
Clinical Pharmacokinetics
|
May 23, 2016
Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
Min Zhu, Benjamin Wu, Christian Brandl, et al.
Langmuir : the ACS Journal of Surfaces and Colloids
|
January 27, 2016
Adsorption Studies of Organophosphonic Acids on Differently Activated Gold Surfaces
Katrin Niegelhell, Simon Leimgruber, Thomas Grießer, et al.
Journal of Clinical Pharmacology
|
September 19, 2017
Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia
Min Zhu, Andrea Kratzer, Jessica Johnson, et al.
International Journal of Cancer
|
February 3, 2005
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
Patrick Hoffmann, Robert Hofmeister, Klaus Brischwein, et al.
International Journal of Cancer
|
September 5, 2002
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
Torsten Dreier, Grit Lorenczewski, Christian Brandl, et al.
Clinical Pharmacokinetics
|
November 26, 2024
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE<sup>®</sup>) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
Mukul Minocha, Corbin G Thompson, Alexis Murphy, et al.
Page
of 2